Labcorp announces first-of-its-kind test for early indication of neurodegenerative diseases and brain injuries using a blood draw

Innovative gfap blood biomarker test expands labcorp's portfolio of tests for diseases including alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries burlington, n.c. , april 15, 2024 /prnewswire/ -- labcorp (nyse: lh), a global leader of innovative and comprehensive laboratory services, today announced the availability of the nation's first test for glial fibrillary acidic protein (gfap), a critical blood-based biomarker for the early detection of neurodegenerative diseases and neurological injuries.
LH Ratings Summary
LH Quant Ranking